



## Company Overview

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

## Kane Biotech Receives Decisions to Grant for Two European Patents Providing Broad Protection of coactiv+™ Technology for Wound Care, Skin Infections and Personal Care Formulations

Jul 29 2021, 8:00 AM EDT

## Kane Biotech Expands its Wound Care and Surgical Portfolio with a coactiv+™ Antimicrobial Hydrogel

Jul 22 2021, 8:00 AM EDT

## Kane Biotech Announces Cancellation of Options and Issuance of Restricted Share Units

Jul 21 2021, 4:30 PM EDT

## Stock Overview

Symbol	KNE
Exchange	TSXV
Market Cap	18.63m
Last Price	\$0.17
52-Week	\$0.11 - \$0.235

07/30/2021 03:47 PM EDT

## Investor Relations

Harbor Access LLC  
Graham Farrell  
Managing Partner  
130 King St. W  
Suite 1900  
Toronto, ON  
T: (416) 842 9003  
graham.farrell@harboraccessllc.com

## Board of Directors

### Mr. Mark Nawacki

Chairman

### Marc Edwards

Director, Interim Chief Executive Officer

### Rashieda Gluck

Director

### Dr. Allan Mandelzys

Director

## Kane Biotech Inc.

162-196 Innovation Drive  
Winnipeg, Manitoba R3T 2N2  
Canada

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.